{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:49:02Z","timestamp":1791258542270,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1602\/neurorx.2.1.120","type":"journal-article","created":{"date-parts":[[2004,12,14]],"date-time":"2004-12-14T18:29:06Z","timestamp":1103048946000},"page":"120-128","source":"Crossref","is-referenced-by-count":107,"title":["Neuroprotection in experimental stroke with targeted neurotrophins"],"prefix":"10.1007","volume":"2","author":[{"given":"Dafang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"20100120_CR1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/01.STR.0000106160.34316.19","volume":"35","author":"JP Broderick","year":"2004","unstructured":"Broderick JP. William M. Feinberg Lecture: stroke therapy in the year 2025. Burden, breakthroughs, and barriers to progress.Stroke 35: 205\u2013211, 2004.","journal-title":"Stroke"},{"key":"20100120_CR2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0022-510X(89)90060-9","volume":"91","author":"C Fieschi","year":"1989","unstructured":"Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours.J Neurol Sci 91: 311\u2013322, 1989.","journal-title":"J Neurol Sci"},{"key":"20100120_CR3","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","volume":"333","author":"The National Institute of Neurological Disorder and Stroke rt-PA Stroke Study Group","year":"1995","unstructured":"The National Institute of Neurological Disorder and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke.N Engl J Med 333: 1581\u20131587, 1995.","journal-title":"N Engl J Med"},{"key":"20100120_CR4","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.282.21.2003","volume":"282","author":"A Furlan","year":"1999","unstructured":"Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute ischemic cerebral thromboembolism.JAMA 282: 2003\u20132011, 1999.","journal-title":"JAMA"},{"key":"20100120_CR5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2125.2003.01939.x","volume":"57","author":"GA Ford","year":"2004","unstructured":"Ford GA, Bryant CA, Mangoni AA, Jackson SHD. Stroke, dementia, and drug delivery.Br J Clin Pharmacol 57: 15\u201326, 2004.","journal-title":"Br J Clin Pharmacol"},{"key":"20100120_CR6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.53.1.3","volume":"53","author":"W Hacke","year":"1999","unstructured":"Hacke W, Brott T, Caplan LR, Meier D, Fieschi C, von Kummer R, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience.Neurology 53[Suppl]: S3-S14, 1999.","journal-title":"Neurology"},{"key":"20100120_CR7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01376517-200304000-00008","volume":"35","author":"JL Hinkle","year":"2003","unstructured":"Hinkle JL, Bowman L. Neuroprotection for ischemic stroke.J Neurosci Nurs 35: 114\u2013118, 2003.","journal-title":"J Neurosci Nurs"},{"key":"20100120_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11910-003-0031-z","volume":"3","author":"B Ovbiagele","year":"2003","unstructured":"Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Neuroprotective agents for the treatment of acute ischemice stroke.Curr Neurol Neurosci Rep 3: 9\u201320, 2003.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"Suppl 1","key":"20100120_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000074808","volume":"17","author":"NG Wahlgren","year":"2004","unstructured":"Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischemia: Facts and fancies\u2014the need for new approaches.Cerebrovascular Dis 17[Suppl 1]: 153\u2013166, 2004.","journal-title":"Cerebrovascular Dis"},{"key":"20100120_CR10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3171\/jns.1993.78.2.0257","volume":"78","author":"SA Menzies","year":"1993","unstructured":"Menzies SA, Betz AL, Hoff JT. Contributions of ions and albumin to the formation and resolution of ischemic brain edema.J Neurosurg 78: 257\u2013266, 1993.","journal-title":"J Neurosurg"},{"key":"20100120_CR11","first-page":"1381","volume":"32","author":"RF Keep","year":"2001","unstructured":"Keep RF. Editorial comment.Stroke 32: 1381\u20131382, 2001.","journal-title":"Stroke"},{"key":"20100120_CR12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev.pharmtox.37.1.239","volume":"37","author":"F Hefti","year":"1997","unstructured":"Hefti F. Pharmacology of neurotrophic factors.Annu Rev Pharmacol Toxicol 37: 239\u2013267, 1997.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"20100120_CR13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-4613-1721-0_9","volume-title":"Neurobiology of amino acid, peptides, and trophic factors","author":"F Hefti","year":"1988","unstructured":"Hefti F, Hartikka JA, Montera CN, Junard EO. Role of nerve growth factor in the central nervous system. In: Neurobiology of amino acid, peptides, and trophic factors (Ferrendelli JA, Collins RC, Johnson EM, eds), pp 127\u2013138. Norwell, MA: Kluwer Academic Publishers, 1988."},{"key":"20100120_CR14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1152\/physrev.1968.48.3.534","volume":"48","author":"R Levi-Montalcini","year":"1968","unstructured":"Levi-Montalcini R, Angeletti PU. Nerve growth factor.Physiol Rev 48: 534\u2013569, 1968.","journal-title":"Physiol Rev"},{"key":"20100120_CR15","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1523\/JNEUROSCI.06-08-02155.1986","volume":"6","author":"F Hefti","year":"1986","unstructured":"Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transactions.J Neurosci 6: 2155\u20132162, 1986.","journal-title":"J Neurosci"},{"key":"20100120_CR16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0166-4328(85)90004-X","volume":"17","author":"B Will","year":"1985","unstructured":"Will B, Hefti F. Behavioral and neurochemical effects of chronic intravenous injection of nerve growth factor in adult rats with fimbria lesions.Behav Brain Res 17: 17\u201324, 1985.","journal-title":"Behav Brain Res"},{"key":"20100120_CR17","doi-asserted-by":"crossref","first-page":"9231","DOI":"10.1073\/pnas.83.23.9231","volume":"33","author":"L William","year":"1986","unstructured":"William L, Varon S, Peterson G, Wictorin K, Bjorklund A, Gage F. Continuous infusion of nerve growth factor prevents basal fore-brain neuronal death after fimbria fomix transection.Proc Natl Acad Sci USA 33: 9231\u20139235, 1986.","journal-title":"Proc Natl Acad Sci USA"},{"key":"20100120_CR18","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1523\/JNEUROSCI.11-09-02914.1991","volume":"11","author":"T Shigeno","year":"1991","unstructured":"Shigeno T, Mima T, Takakura K, Graham DI, Kato G, et al. Amelioration of delayed neuronal death in the hippocampus by nerve growth factor.J Neurosci 11: 2914\u20132919, 1991.","journal-title":"J Neurosci"},{"key":"20100120_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02257624","volume":"4","author":"L Olson","year":"1992","unstructured":"Olson L, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I, et al. Nerve growth factor affects C-11 nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report).J Neural Transm 4: 79\u201395, 1992.","journal-title":"J Neural Transm"},{"key":"20100120_CR20","first-page":"1","volume-title":"Peptide drug delivery to the brain","author":"WM Pardridge","year":"1991","unstructured":"Pardridge WM. Peptide drug delivery to the brain. New York: Raven Press, 1\u2013357, 1991."},{"key":"20100120_CR21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/363266a0","volume":"363","author":"CE Henderson","year":"1993","unstructured":"Henderson CE, Camu W, Mettling C, Gouin A, Poulsen K, Karihaloo M, et al. Neurotrophins promote motor neuron survival and are present in embryonic limb bud.Nature 363: 266\u2013270, 1993.","journal-title":"Nature"},{"key":"20100120_CR22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/B978-0-08-057132-4.50012-5","volume-title":"Neurotrophic factors","author":"RM Lindsay","year":"1993","unstructured":"Lindsay RM. Brain-derived neurotrophic factor: an NGF related neurotrophin. In: Neurotrophic factors (Fallon JH, Loughlin SE, eds), pp 257\u2013284. New York: Academic Press, 1993."},{"key":"20100120_CR23","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1126\/science.8066451","volume":"265","author":"H Mitsumoto","year":"1994","unstructured":"Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrests of motor neuron disease in Wobbler mice cotreated with CNTF and BDNF.Science 265: 1107\u20131110, 1994.","journal-title":"Science"},{"key":"20100120_CR24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/360753a0","volume":"360","author":"Q Yan","year":"1992","unstructured":"Yan Q, Elliott J, Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death.Nature 360: 753\u2013755, 1992.","journal-title":"Nature"},{"key":"20100120_CR25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1227\/00006123-199402000-00016","volume":"34","author":"T Tsukahara","year":"1994","unstructured":"Tsukahara T, Yonekawa MD, Tanaka K, Ohara O, Watanabe S, et al. The role of brain-derived neurotrophic factor in transient fore-brain ischemia in the rat brain.Neurosurgery 34: 323, 1994.","journal-title":"Neurosurgery"},{"key":"20100120_CR26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ana.410380629","volume":"38","author":"WG Bradley","year":"1995","unstructured":"Bradley WG. A phase I\/II study of recombinant brain-derived neurotrophic factor in patients with ALS.Ann Neurol 38: 971, 1995.","journal-title":"Ann Neurol"},{"key":"20100120_CR27","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1212\/WNL.52.7.1427","volume":"52","author":"The BDNF Study Group (Phase III)","year":"1999","unstructured":"The BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS.Neurology 52: 1427\u20131433, 1999.","journal-title":"Neurology"},{"key":"20100120_CR28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14660820050515197","volume":"1","author":"G Ochs","year":"2000","unstructured":"Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, et al. A phase I\/II trial of recombinant methionyl human brain derived neurotrophic factor administrated by intrathecal infusion to patients with amyotrophic lateral sclerosis.Amyotroph Lateral Scler Other Motor Neuron Disord 1: 201\u2013206, 2000.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"20100120_CR29","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1023\/A:1018940732550","volume":"11","author":"WM Pardridge","year":"1994","unstructured":"Pardridge WM, Kang Y-S, Buciak JL. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery.Pharma Res 11: 738\u2013746, 1994.","journal-title":"Pharma Res"},{"key":"20100120_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(08)60821-0","volume":"60","author":"DE Johnson","year":"1993","unstructured":"Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family.Adv Cancer Res 60: 1\u201341, 1993.","journal-title":"Adv Cancer Res"},{"key":"20100120_CR31","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1957172","volume":"254","author":"P Cuevas","year":"1991","unstructured":"Cuevas P, Carceller F, Ortega S, Zazo M, Nieto I, Gimenez-Gallego G. Hypotensive activity of fibroblast growth factor.Science 254: 1208\u20131210, 1991.","journal-title":"Science"},{"key":"20100120_CR32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/jcbfm.1994.11","volume":"14","author":"S Rosenblatt","year":"1994","unstructured":"Rosenblatt S, Irikura K, Caday CG, Finklestein SP, Moskowitz MA. Basic fibroblast growth factor dilates rat pial arterioles.J Cereb Blood Flow Metab 14: 70\u201374, 1994.","journal-title":"J Cereb Blood Flow Metab"},{"key":"20100120_CR33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000015941","volume":"9","author":"H Ay","year":"1999","unstructured":"Ay H, Ay I, Joroshetz WJ, Finklestein SP. Potential usefulness of basic fibroblast growth factor as a treatment for stroke.Cerebrovascular Dis 9: 131\u2013135, 1999.","journal-title":"Cerebrovascular Dis"},{"key":"20100120_CR34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1007570509232","volume":"17","author":"Y Deguchi","year":"2000","unstructured":"Deguchi Y, Naito T, Yuga T, Furukawa A, Yamada S, Pardridge WM, et al. Blood-brain barrier transport of I-125 labeled fibroblast growth factor.Pharma Res 17: 63\u201369, 2000.","journal-title":"Pharma Res"},{"key":"20100120_CR35","first-page":"287","volume":"29","author":"The FIBLAST Safety Study Group","year":"1998","unstructured":"The FIBLAST Safety Study Group. Clinical safety of intravenous bFGF in acute stroke.Stroke 29: 287, 1998.","journal-title":"Stroke"},{"key":"20100120_CR36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000065683","volume":"14","author":"J Bogousslavsky","year":"2002","unstructured":"Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, et al. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II\/III safety and efficacy trial.Cerebrovas Dis 14: 239\u2013251, 2002.","journal-title":"Cerebrovas Dis"},{"key":"20100120_CR37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/312162a0","volume":"312","author":"WA Jefflies","year":"1984","unstructured":"Jefflies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries.Nature 312: 162\u2013163, 1984.","journal-title":"Nature"},{"key":"20100120_CR38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/978-1-4615-0123-7_15","volume":"513","author":"WM Pardridge","year":"2002","unstructured":"Pardridge WM. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins.Adv Exp Med Biol 513: 397\u2013430, 2002.","journal-title":"Adv Exp Med Biol"},{"key":"20100120_CR39","first-page":"77","volume":"279","author":"D Wu","year":"1996","unstructured":"Wu D, Pardridge WM. Central nervous system pharmacologie effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.J Pharmacol Exper Ther 279: 77\u201383, 1996.","journal-title":"J Pharmacol Exper Ther"},{"key":"20100120_CR40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1073\/pnas.96.1.254","volume":"96","author":"D Wu","year":"1999","unstructured":"Wu D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain.Proc Natl Acad Sci USA 96: 254\u2013259, 1999.","journal-title":"Proc Natl Acad Sci USA"},{"key":"20100120_CR41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/10611860290022679","volume":"10","author":"D Wu","year":"2002","unstructured":"Wu D, Song B-W, Vinters HV, Pardridge WM. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system.J Drug Target 10: 239\u2013245, 2002.","journal-title":"J Drug Target"},{"key":"20100120_CR42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0006-8993(00)03108-5","volume":"889","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor (BDNF) to a blood-brain barrier targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin.Brain Res 889: 49\u201356, 2001.","journal-title":"Brain Res"},{"key":"20100120_CR43","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/01.STR.32.6.1378","volume":"32","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Pardridge WM. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system.Stroke 32: 1378\u20131384, 2001.","journal-title":"Stroke"},{"key":"20100120_CR44","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.169.3951.1217","volume":"169","author":"SI Said","year":"1970","unstructured":"Said SI, Mutt V. Polypeptide with broad biological activity. Isolation from small intestine.Science 169: 1217\u20131218, 1970.","journal-title":"Science"},{"key":"20100120_CR45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0006-8993(84)91175-2","volume":"322","author":"Y Suzuki","year":"1984","unstructured":"Suzuki Y, McMaster D, Lederis K, Rorstad OP. Characterization of relaxant effects of vasoactive intestinal peptide (VIP) and PHI on isolated brain arteries.Brain Res 322: 9\u201316, 1984.","journal-title":"Brain Res"},{"key":"20100120_CR46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/jcbfm.1987.69","volume":"7","author":"TL Yaksh","year":"1987","unstructured":"Yaksh TL, Wang J-Y, Go VLW. Cortical vasodilatation produced by vasoactive intestinal peptide (VIP) and by physiological stimuli in the rat.J Cereb Blood Flow Metab 7: 315\u2013326, 1987.","journal-title":"J Cereb Blood Flow Metab"},{"key":"20100120_CR47","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1172\/JCI118672","volume":"97","author":"DE Brenneman","year":"1996","unstructured":"Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide.J Clin Invest 97: 2299\u20132307, 1996.","journal-title":"J Clin Invest"},{"key":"20100120_CR48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/335639a0","volume":"335","author":"DE Brenneman","year":"1988","unstructured":"Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, et al. Neuronal cell killing by the envelope protein HIV and its prevention by vasoactive intestinal peptide.Nature 335: 639\u2013642, 1988.","journal-title":"Nature"},{"key":"20100120_CR49","first-page":"161","volume":"273","author":"I Gozes","year":"1995","unstructured":"Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, Davidson A, et al. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors.J Pharmacol Exper Ther 273: 161\u2013167, 1995.","journal-title":"J Pharmacol Exper Ther"},{"key":"20100120_CR50","first-page":"H449","volume":"238","author":"J McCulloch","year":"1980","unstructured":"McCulloch J, Edvinsson L. Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide.Am J Physiol (Lond) 238: H449-H456, 1980.","journal-title":"Am J Physiol (Lond)"},{"key":"20100120_CR51","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1073\/pnas.90.7.2618","volume":"90","author":"U Bickel","year":"1993","unstructured":"Bickel U, Yoshikawa T, Landaw EM, Faull KF, Pardridge WM. Pharmacologic effects in vivo in brain by vector-mediated peptide delivery.Proc Natl Acad Sci USA 90: 2618\u20132622, 1993.","journal-title":"Proc Natl Acad Sci USA"},{"key":"20100120_CR52","first-page":"344","volume":"269","author":"Y-S Kang","year":"1994","unstructured":"Kang Y-S, Pardridge WM. Use of neutral-avidin improves pharmacokinetics and brain delivery of biotin bound to an avidinmonoclonal antibody conjugate.J Pharmacol Exper Ther 269: 344\u2013350, 1994.","journal-title":"J Pharmacol Exper Ther"},{"key":"20100120_CR53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/10611869509059215","volume":"3","author":"Y-S Kang","year":"1995","unstructured":"Kang Y-S, Saito Y, Pardridge WM. Pharmacokinetics of [3H]biotin bound to different avidin analogues.J Drug Target 3: 159\u2013165, 1995.","journal-title":"J Drug Target"},{"key":"20100120_CR54","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1023\/A:1011981927620","volume":"15","author":"WM Pardridge","year":"1998","unstructured":"Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration.Pharma Res 15: 576\u2013582, 1998.","journal-title":"Pharma Res"},{"key":"20100120_CR55","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.STR.31.9.2212","volume":"31","author":"W-R Schabitz","year":"2000","unstructured":"Schabitz W-R, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia.Stroke 31: 2212\u20132217, 2000.","journal-title":"Stroke"},{"key":"20100120_CR56","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.301.2.605","volume":"301","author":"B-W Song","year":"2002","unstructured":"Song B-W, Vinters HV, Wu D, Pardridge WM. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector.J Pharmacol Exper Ther 301: 605\u2013610, 2002.","journal-title":"J Pharmacol Exper Ther"},{"key":"20100120_CR57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00000441-200207000-00004","volume":"324","author":"M Berger","year":"2002","unstructured":"Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies.Am J Med Sci 324: 14\u201330, 2002.","journal-title":"Am J Med Sci"},{"key":"20100120_CR58","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.4049\/jimmunol.158.10.4797","volume":"158","author":"SU Shin","year":"1997","unstructured":"Shin SU, Wu D, Ramanathan R, Pardridge WM, Morrison SL. Functional and pharmacokinetic properties of antibody-avidin fusion proteins.J Immunol 158: 4797\u20134804, 1997.","journal-title":"J Immunol"},{"key":"20100120_CR59","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511549571","volume-title":"Brain drug targeting. The future of brain drug development","author":"WM Pardridge","year":"2001","unstructured":"Pardridge WM. Brain drug targeting. The future of brain drug development. Cambridge, UK: Cambridge University Press, 2001."},{"key":"20100120_CR60","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI119708","volume":"100","author":"D Wu","year":"1997","unstructured":"Wu D, Yang J, Pardridge WM. Drug targeting of a peptide radio-pharmaceutical through the primary blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.J Clin Invest 100: 1804\u20131812, 1997.","journal-title":"J Clin Invest"},{"key":"20100120_CR61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1007592720793","volume":"17","author":"MJ Coloma","year":"2000","unstructured":"Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, Morrison SL, Pardridge WM. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor.Pharm Res 17: 266\u2013274, 2000.","journal-title":"Pharm Res"},{"key":"20100120_CR62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/00207450490249329","volume":"114","author":"SA Ataus","year":"2004","unstructured":"Ataus SA, Onal MZ, Ozdem SS, Locke KW, Balkan S. The effects of citicoline and lamotrigine alone and in combination following permanent middle cerebral artery occlusion in rats.Int J Neurosci 114: 183\u2013196, 2004.","journal-title":"Int J Neurosci"},{"issue":"Suppl 1","key":"20100120_CR63","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1331\/154434504322904604","volume":"44","author":"JC Bradberry","year":"2004","unstructured":"Bradberry JC, Fagan SC, Gray DR, Moon YS. New perspectives on the pharmacotherapy of ischemic stroke.J Am Pharm Assoc 44[2 Suppl 1]: S46-S56, 2004.","journal-title":"J Am Pharm Assoc"},{"key":"20100120_CR64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00129784-200202050-00003","volume":"2","author":"SD Chen","year":"2002","unstructured":"Chen SD, Lee JM, Yang DI, Nassief A, Hsu CY. Combination therapy for ischemic stroke: potential of neuroprotectants plus thrombolytics.Am J Cardiovasc Drugs 2: 303\u2013313, 2002.","journal-title":"Am J Cardiovasc Drugs"},{"key":"20100120_CR65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0306-4522(02)00912-0","volume":"118","author":"M Sobrado","year":"2003","unstructured":"Sobrado M, Lopez MG, Carceller F, Garcia AG, Roda JM. Combined nimodipine and citicoline reduce infarct size, attenuation apoptosis and increase bcl-2 expression after focal cerebral ischemia.Neuroscience 118: 107\u2013113, 2003.","journal-title":"Neuroscience"},{"key":"20100120_CR66","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/ajhp\/59.18.1723","volume":"59","author":"J Nappi","year":"2002","unstructured":"Nappi J, Talbert R. Dual antiplatelet therapy for prevention of recurrent ischemic events.Am J Health Syst Pharm 59: 1723\u20131735, 2002.","journal-title":"Am J Health Syst Pharm"},{"key":"20100120_CR67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/01.STR.30.2.427","volume":"30","author":"WR Schabitz","year":"1999","unstructured":"Schabitz WR, Li F, Irie K, Sandage BW Jr, Locke KW, Fisher M. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia.Stroke 30: 427\u2013431, 1999.","journal-title":"Stroke"}],"container-title":["NeuroRX"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1602\/neurorx.2.1.120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T22:00:47Z","timestamp":1682892047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1602\/neurorx.2.1.120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":67,"aliases":["10.1007\/bf03206648"],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["20100120"],"URL":"https:\/\/doi.org\/10.1602\/neurorx.2.1.120","relation":{},"ISSN":["1545-5343"],"issn-type":[{"value":"1545-5343","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}